	US 11,999,795 B2
	Monoclonal antibody and use thereof
Takashi Fukuyama, Sagamihara (JP); Hitoshi Yamazaki, Sagamihara (JP); Mariko Ogi, Sagamihara (JP); Noritada Kobayashi, Sagamihara (JP); Yoshinobu Ichiki, Fukuoka (JP); and Masahiko Hatakeyama, Tokyo (JP)
Assigned to SCHOOL JURIDICAL PERSON THE KITASATO INSTITUTE, Tokyo (JP)
Appl. No. 16/763,386
Filed by SCHOOL JURIDICAL PERSON THE KITASATO INSTITUTE, Tokyo (JP)
PCT Filed Nov. 9, 2018, PCT No. PCT/JP2018/041642 § 371(c)(1), (2) Date Dec. 2, 2020, PCT Pub. No. WO2019/098133, PCT Pub. Date May 23, 2019.
Claims priority of application No. 2017-218872 (JP), filed on Nov. 14, 2017.
Prior Publication US 2021/0079110 A1, Mar. 18, 2021
Int. Cl. G01N 33/53 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)

CPC C07K 16/30 (2013.01) [G01N 33/574 (2013.01); G01N 33/57492 (2013.01); C07K 2317/565 (2013.01)]

11 Claims

1. A monoclonal antibody or an antigen binding fragment thereof that binds Kitakyushu lung cancer antigen-I (KK-LC-1), wherein the antibody or antigen binding fragment thereof comprises: heavy-chain complementarity-determining regions (CDRs) 1 to 3 that respectively consist of amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 that respectively consist of amino acid sequences of SEQ ID NOs: 5 to 7.